Healthcare Industry News: stem cell therapeutics
News Release - March 15, 2007
NeoStem Hires Experienced Marketing Executive Arlene Graime to Direct Government Affairs and Raise Nationwide Consumer Awareness
New Hire Further Strengthens Senior Management to Accelerate Business Development Programs and Target Key Government AgenciesNEW YORK--(HSMN NewsFeed)--NeoStem, Inc. (OTCBB:NEOI ), the first company to specialize in the collection, processing and storage of stem cells from adult donors for personal use in times of critical medical need, announced today the further expansion of its program to commercialize the Company's proprietary processes and first-to-market competitive advantage to a vast, nationwide consumer base with the hiring of Arlene Graime as Director, Government Affairs and Special Projects.
In her new position, Ms. Graime will spearhead initiatives aimed at working with key federal and state agencies, and crucial Congressional committees in order to raise awareness for the benefits of adult stem cell therapy as a treatment option. NeoStem believes that the use of its proprietary collection, processing and storing capabilities could significantly increase the chances of survival for first-responders, such as firefighters, police officers and the National Guard, who are at risk of suffering from radiation exposure.
"NeoStem is entering a new growth period that will require significant support to maximize our capabilities," said Robin Smith, M.D., Chief Executive Officer of NeoStem. "We believe that Arlene will provide us with the proper guidance and support to reach targeted key government agencies and to raise nationwide consumer awareness for NeoStem's next generation health services. We are fully committed to commercializing our services and to building shareholder value."
Ms. Graime has had an accomplished and multifaceted career in corporate marketing, special event planning and working with the House of Representatives. She also worked with key staff members of two White House administrations.
As the Senior Director of Marketing at Coach, Inc., she directed an executive sales team that introduced new marketing strategies, processes and procedures that successfully achieved financial objectives. She also served as the National Director of Events for the United States Olympic Committee, working on diplomatic efforts to promote goodwill and sportsmanship through public relations with United States and International Olympic athletes.
"NeoStem offers a rare opportunity to join a world-class team of executives working in the early stages of the next healthcare revolution," said Ms. Graime. "My experience will serve to develop the strategies that communicate the promise of adult stem cells to a general audience. I look forward to contributing to NeoStem and furthering the Company's vision."
NeoStem is developing a nationwide health-industry network to capitalize on the predicted $8.5 billion-dollar stem cell therapeutics industry. NeoStem's visionary senior management, non-capital intensive business model and proprietary processes are making an immediate impact in what many believe to be the "next big thing in consumer health marketing." The Company has termed this paradigm shift in the medical industry as "bio-insurance," which empowers health-conscious adults to have their own (autologous) stem cells collected and banked to ensure prompt access for therapeutic use in times of critical medical need.
About NeoStem, Inc.
NeoStem offers pioneering services intended to capitalize on developing therapies in the thriving field of adult stem cell research. NeoStem offers its clients bio-insurance, including proprietary processes that provide health conscious individuals the opportunity to store their own (autologous) stem cells for long periods of time to ensure prompt access in times of critical medical need. NeoStem's visionary senior management, its non-capital intensive business model and portfolio of first-to-market proprietary technology will allow the Company to exploit a competitive advantage that leverages the burgeoning field of adult stem cell therapeutics, an anticipated multibillion dollar industry. Targeted markets for current adult stem cell treatments in development include autoimmune diseases, cancer, heart disease, diabetes, and many more.
NeoStem is committed to continue capitalizing on some of today's most promising therapeutics in development well into the 21st Century. For more information, please visit: www.neostem.com.
For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/neostem/. To view current stock quotes and news, visit http://www.trilogy-capital.com/tcp/neostem/quote.html. To view an investor fact sheet about the company, visit http://www.trilogy-capital.com/tcp/neostem/factsheet.html.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, the future of regenerative medicine and the role of adult stem cells in that future, the future use of adult stem cells as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business and obtain appropriate state licenses; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control and (v) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at www.sec.gov under "Search for Company Filings."
Pursuant to an October 1, 2006 agreement, Consulting For Strategic Growth I, Ltd. ("CFSG1") provides the Company with consulting, business advisory, investor relations, public relations and corporate development services, for which CFSG1 receives a fixed monthly fee for the duration of the agreement and received shares of NeoStem's common stock. Independent of CFSG1's receipt of cash or other compensation from the Company, CFSG1 may choose to purchase the common stock of the Company and thereafter sell those shares at any time it deems appropriate to do so. For more information, please visit www.cfsg1.com.
Source: NeoStem
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
